AN2 Therapeutics SEC Filing Effectiveness Notice
Ticker: ANTX · Form: EFFECT · Filed: Apr 21, 2026 · CIK: 0001880438
| Field | Detail |
|---|---|
| Company | An2 Therapeutics, Inc. (ANTX) |
| Form Type | EFFECT |
| Filed Date | Apr 21, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: effectiveness, registration-statement, sec-filing
TL;DR
AN2 Therapeutics just got SEC effectiveness on their filing. Big step for them.
AI Summary
AN2 Therapeutics, Inc. filed an EFFECT form with the SEC on April 21, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001256, relates to Act 33 and has file number 333-294956.
Why It Matters
This filing signifies that a registration statement for AN2 Therapeutics, Inc. has become effective, which is a crucial step for potential stock offerings or other securities transactions.
Risk Assessment
Risk Level: low — This filing is a procedural notice of effectiveness and does not inherently contain new financial risks.
Key Numbers
- 2026-04-21 — Filing Date (Date the EFFECT filing was accepted by the SEC.)
- 2026-04-20 — Effectiveness Date (The date the registration statement became effective.)
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Filer
- 9999999995-26-001256 (dollar_amount) — SEC Accession Number
- 2026-04-21 (dollar_amount) — Filing Acceptance Date
- 2026-04-20 (dollar_amount) — Effectiveness Date
- 333-294956 (dollar_amount) — File Number
FAQ
What type of filing is this?
This is an EFFECT filing, which signifies a Notice of Effectiveness for a registration statement.
Who is the filer?
The filer is AN2 Therapeutics, Inc., with CIK 0001880438.
When was the filing accepted by the SEC?
The filing was accepted on April 21, 2026.
What is the effectiveness date mentioned in the filing?
The effectiveness date is April 20, 2026.
What is the file number associated with this filing?
The file number is 333-294956.
Filing Details
This Form EFFECT (Form EFFECT) was filed with the SEC on April 21, 2026 regarding AN2 Therapeutics, Inc. (ANTX).